Abstract 16728: High Leptin Predicts Short-Term Major Adverse Cardiac Events in Patients With Coronary Artery Disease
Introduction: Leptin is a peptide hormone secreted mainly by adipose tissue. It has been associated with several cardiovascular risk factors. We examined whether plasma leptin predicts major adverse cardiac events (MACE) in a two-year follow-up of patients with coronary artery disease (CAD).
Methods: The study population consisted of 1,678 CAD patients. At baseline, fasting plasma leptin levels were measured and an extensive cardiovascular examination performed. The patients were followed up for two years. MACE was defined as acute coronary syndrome, revascularization, hospitalization for congestive heart failure or cardiac death. Hazard ratios were estimated by Cox’s regression model adjusted for age, sex, body mass index, stage of the glucose metabolism disorder, systolic blood pressure, LDL, history of smoking, history of myocardial infarction and, in the case of hospitalization for congestive heart failure, 2-dimensional ejection fraction and ratio of peak early diastolic mitral velocity to tissue Doppler-deriver peak early diastolic mitral annular velocity (E/E’).
Results: The patients in the highest leptin quartile were at a higher risk of MACE compared to the patients in the lowest leptin quartile (HR 1.95, 95 % CI 1.10 to 3.46; p=0.022). High leptin levels predicted most powerfully the risk of hospitalization for congestive heart failure (HR 10.45, 95 % CI 1.84 to 59.48; p=0.008 in the highest leptin quartile compared to the lowest leptin quartile) and the risk of cardiac death (HR 12.50, 95 % CI 1.01 to 154.92; p<0.050 in the highest leptin quartile compared to the lowest leptin quartile).
Conclusions: We conclude that high plasma leptin predicts short-term major adverse cardiac events in patients with CAD independent of traditional risk factors. High leptin levels predict especially hospitalization for congestive heart failure and cardiac death. The possible detrimental effects of leptin on the cardiovascular system must be thoroughly investigated.
Author Disclosures: V. Puurunen: None. O. Ukkola: None. E. Lepojärvi: None. O. Piira: None. M. Junttila: None. H.V. Huikuri: None.
- © 2014 by American Heart Association, Inc.